caspase cascade

3,6-Dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway.

Diclofenac (Diclofenacum) is a nonsteroidal benzeneacetic acid derivative with anti-inflammatory activity. Diclofenac binds and chelates both isoforms of cyclooxygenase (COX-1 and-2), thereby blocking the conversion of arachidonic acid to pro-inflammatory-proprostaglandins.

Diclofenac Diethylamine, a non-selective COX inhibitor, is utilized as a nonsteroidal anti-inflammatory drug (NSAID).

Diclofenac sodium (GP 45840) is a non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.

Diclofenac Potassium (CGP-45840B) is a nonsteroidal anti-inflammatory drug taken to reduce inflammation and as an analgesic reducing pain in certain conditions.

SF5 is an inhibitor of the apoptosis pathway. Which is through the JNK-p53-caspase apoptotic cascade.

Microtubule destabilizing agent-2 (Compound 21) is an orally active and selective anticancer compound targeting microtubule proteins. It disrupts microtubule stability, inhibiting microtubule polymerization. This agent causes human tumor cells to arrest in the G0/G1 phase and induces apoptosis (Apoptosis) through activation of the Caspase cascade pathway. Additionally, it exhibits anti-inflammatory properties, inhibiting the production of TNF-α and IL-6 in vitro. Microtubule destabilizing agent-2 also suppresses tumor growth in xenograft mice.

Tubulin-IN-52 is a potent, selective tubulin polymerization inhibitor with an IC₅₀ of 2.9 μM. Tubulin-IN-52 induces apoptosis in tumor cells by triggering a caspase cascade via the mitochondrial apoptosis pathway. Tubulin-IN-52 significantly inhibits tumor growth without significant toxicity. Tubulin-IN-52 can be used in cancer-related research.

Fascaplysin is a cyclin D kinase 4/ cyclin D1 inhibitor (IC50 = 0.35 μM). Fascaplysin induces caspase mediated crosstalk between autophagy and apoptosis through the inhibition of PI3K/AKT/mTOR signaling cascade in human leukemia HL-60 cells.

Nemorosone is a polycyclic polyprenylated acylphloroglucinol (PPAP) originally isolated from C. rosea that has antiproliferative properties.1 Nemorosone inhibits growth of NB69, Kelly, SK-N-AS, and LAN-1 neuroblastoma cells (IC50s = 3.1-6.3 μM), including several drug-resistant clones, but not MRC-5 human embryonic fibroblasts (IC50 = >40 μM).2 It increases DNA fragmentation in LAN-1 cells in a dose-dependent manner, and decreases N-Myc protein levels and phosphorylation of ERK1/2 by MEK1/2. Nemorosone also inhibits growth of Capan-1, AsPC-1, and MIA-PaCa-2 pancreatic cancer cells (IC50s = 4.5-5.0 μM following a 72-hour treatment) but not human dermal and foreskin fibroblasts (IC50s = >35 μM).1 It induces apoptosis, abolishes the mitochondrial membrane potential, and increases cytosolic calcium concentration in pancreatic cancer cells in a dose-dependent manner. Nemorosone activates the caspase cascade in a dose-dependent manner and inhibits cell cycle progression, increasing the proportion of cells in the G0/G1 phase, in both neuroblastoma and pancreatic cancer cells.1,2 Nemorosone (50 mg/kg, i.p., per day) also reduces tumor growth in an MIA-PaCa-2 mouse xenograft model.3References1. Holtrup, F., Bauer, A., Fellenberg, K., et al. Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br. J. Pharmacol. 162(5), 1045-1059 (2011).2. Díaz-Carballo, D., Malak, S., Bardenheuer, W., et al. Cytotoxic activity of nemorosone in neuroblastoma cells. J. Cell. Mol. Med. 12(6B), 2598-2608 (2008).3. Wold, R.J., Hilger, R.A., Hoheisel, J.D., et al. In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts. PLoS One 8(9), e74555 (2013). Nemorosone is a polycyclic polyprenylated acylphloroglucinol (PPAP) originally isolated from C. rosea that has antiproliferative properties.1 Nemorosone inhibits growth of NB69, Kelly, SK-N-AS, and LAN-1 neuroblastoma cells (IC50s = 3.1-6.3 μM), including several drug-resistant clones, but not MRC-5 human embryonic fibroblasts (IC50 = >40 μM).2 It increases DNA fragmentation in LAN-1 cells in a dose-dependent manner, and decreases N-Myc protein levels and phosphorylation of ERK1/2 by MEK1/2. Nemorosone also inhibits growth of Capan-1, AsPC-1, and MIA-PaCa-2 pancreatic cancer cells (IC50s = 4.5-5.0 μM following a 72-hour treatment) but not human dermal and foreskin fibroblasts (IC50s = >35 μM).1 It induces apoptosis, abolishes the mitochondrial membrane potential, and increases cytosolic calcium concentration in pancreatic cancer cells in a dose-dependent manner. Nemorosone activates the caspase cascade in a dose-dependent manner and inhibits cell cycle progression, increasing the proportion of cells in the G0/G1 phase, in both neuroblastoma and pancreatic cancer cells.1,2 Nemorosone (50 mg/kg, i.p., per day) also reduces tumor growth in an MIA-PaCa-2 mouse xenograft model.3 References1. Holtrup, F., Bauer, A., Fellenberg, K., et al. Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br. J. Pharmacol. 162(5), 1045-1059 (2011).2. Díaz-Carballo, D., Malak, S., Bardenheuer, W., et al. Cytotoxic activity of nemorosone in neuroblastoma cells. J. Cell. Mol. Med. 12(6B), 2598-2608 (2008).3. Wold, R.J., Hilger, R.A., Hoheisel, J.D., et al. In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts. PLoS One 8(9), e74555 (2013).

YO-2 is a selective plasmin inhibitor. YO-2 induces thymocyte apoptosis via activation of caspase cascade.

Antiproliferative agent-23, a microtubule-destabilizing agent (MDA), disrupts the tubulin-microtubule system, leading to apoptosis through a mitochondrion-dependent pathway. This involves downregulation of Bcl-2 protein, upregulation of Bax and Cyt c proteins, and activation of the caspase cascade. Additionally, it induces reactive oxygen species (ROS)-mediated endoplasmic reticulum stress in A549/CDDP cells (cisplatin-resistant cancer cell line) through the PERK/ATF4/CHOP signaling pathway, demonstrating anti-tumor activity [1].

Diclofenac-D4 sodium is the deuterated form of Diclofenac sodium (T1555). Diclofenac Sodium (GP 45840) is an effective, non-selective anti-inflammatory agent that acts as a COX inhibitor, with IC50 values of 4 nM for human COX-1 and 1.3 nM for COX-2 in CHO cells. For sheep COX-1 and COX-2, the IC50 values are 5.1 μM and 0.84 μM, respectively. Diclofenac Sodium induces apoptosis in neural stem cells by activating the caspase cascade [apoptosis].

Diclofenac sodium (Standard) is the reference standard of diclofenac sodium, suitable for quantitative analysis, quality control, biochemical experiments, and related research. Diclofenac sodium is a non-selective anti-inflammatory drug and a cyclooxygenase (COX) inhibitor. In CHO cells, its IC₅₀ values against human COX-1 and COX-2 are 4 nM and 1.3 nM, respectively; against ovine COX-1 and COX-2, they are 5.1 μM and 0.84 μM, respectively. In addition, diclofenac sodium induces apoptosis in neural stem cells by activating the caspase cascade.

γ-Eudesmol ((+)-γ-Eudesmol) is a compound that induces apoptosis through mitochondrial pathways. It binds to mitochondrial membrane proteins, causing depolarization of the mitochondrial membrane potential and activates the caspase cascade. This compound exhibits cytotoxicity against various tumor cell lines, such as HepG2 and B16-F10, with IC50 values ranging from 8.86 to 15.15 μg/mL. γ-Eudesmol holds potential for research in cancers including hepatocellular carcinoma and melanoma.